Company intelligence / Profile preview

Chymal Therapeutics

Ownership: Private
Development stage: Preclinical

Overview

Chymal Therapeutics Inc. describes itself as a pioneering biotechnology startup focused on developing next-generation cellular therapies for autoimmune and related diseases. No clinical results are publicly available[2].

Therapeutic areas: Immunology
Modalities: Cellular therapies (specifics not detailed in available sources)
Industry: Biotech

Drug pipeline

1 asset

CHY-001

Pre-clinical

Indications: Graft versus host disease, Crohn's disease, Ulcerative colitis

Beyond the preview

Go deeper on Chymal Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chymal Therapeutics.

Explore the full profile